On 2026-08-11, the clinical trial registry listing for corticotropin, marketed as Acthar, was updated to reflect a status change. The study, titled "Use of Acthar in Rheumatoid Arthritis (RA) Related Flares," is registered under identifier NCT02541955. It is a Phase 4 trial and its current status is listed as completed. Corticotropin is an approved compound. This update reflects only a change in the trial's recorded status on the registry as of the date given. No outcome data, efficacy findings, or safety conclusions are included in this update. The trial record does not specify results at this time, and none should be assumed from a completed status alone. Readers interested in the trial's design, enrollment, or eventual results can consult the registry listing directly using the trial identifier. For general background on corticotropin, including its approved uses and regulatory status, readers can refer to the compound overview for additional context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT02541955"]